Nymox Pharmaceutical Corporation (NYMX)
USD 0.2
(-0.05%)
USD 0.2
(-0.05%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2022 | 1.62 Million USD | 12.61% |
| 2021 | 1.44 Million USD | -66.77% |
| 2020 | 4.34 Million USD | -20.88% |
| 2019 | 5.48 Million USD | -32.03% |
| 2018 | 8.07 Million USD | 724.92% |
| 2017 | 979 Thousand USD | -52.41% |
| 2016 | 2.05 Million USD | 188.85% |
| 2015 | 712.23 Thousand USD | -49.93% |
| 2014 | 1.42 Million USD | 47.2% |
| 2013 | 966.38 Thousand USD | -44.91% |
| 2012 | 1.75 Million USD | -72.48% |
| 2011 | 6.37 Million USD | -52.78% |
| 2010 | 13.5 Million USD | 1138.25% |
| 2009 | 1.09 Million USD | -73.19% |
| 2008 | 4.06 Million USD | -4.52% |
| 2007 | 4.26 Million USD | 7.29% |
| 2006 | 3.97 Million USD | 6.77% |
| 2005 | 3.71 Million USD | -8.53% |
| 2004 | 4.06 Million USD | -1.37% |
| 2003 | 4.12 Million USD | -5.42% |
| 2002 | 4.35 Million USD | 3.97% |
| 2001 | 4.19 Million USD | -7.22% |
| 2000 | 4.51 Million USD | 111.1% |
| 1999 | 2.14 Million USD | -42.5% |
| 1998 | 3.72 Million USD | 38.0% |
| 1997 | 2.69 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 Q2 | 271 Thousand USD | -52.87% |
| 2023 Q1 | 575 Thousand USD | -64.62% |
| 2022 Q2 | 4.47 Million USD | 261.39% |
| 2022 Q1 | 1.23 Million USD | -14.21% |
| 2022 FY | 1.62 Million USD | 12.61% |
| 2022 Q4 | 1.62 Million USD | -48.26% |
| 2022 Q3 | 3.14 Million USD | -29.79% |
| 2021 Q4 | 1.44 Million USD | -62.53% |
| 2021 Q3 | 3.85 Million USD | -42.26% |
| 2021 Q1 | 1.45 Million USD | -66.5% |
| 2021 Q2 | 6.67 Million USD | 358.42% |
| 2021 FY | 1.44 Million USD | -66.77% |
| 2020 Q2 | 1.05 Million USD | -68.7% |
| 2020 FY | 4.34 Million USD | -20.88% |
| 2020 Q4 | 4.34 Million USD | -24.34% |
| 2020 Q3 | 5.74 Million USD | 444.08% |
| 2020 Q1 | 3.37 Million USD | -38.59% |
| 2019 Q2 | 9.51 Million USD | -19.36% |
| 2019 Q1 | 11.8 Million USD | 46.11% |
| 2019 FY | 5.48 Million USD | -32.03% |
| 2019 Q4 | 5.48 Million USD | -26.44% |
| 2019 Q3 | 7.46 Million USD | -21.58% |
| 2018 Q4 | 8.07 Million USD | 68.99% |
| 2018 FY | 8.07 Million USD | 724.92% |
| 2018 Q2 | 5.16 Million USD | 441.51% |
| 2018 Q3 | 4.77 Million USD | -7.49% |
| 2018 Q1 | 954 Thousand USD | -2.55% |
| 2017 Q2 | 1.32 Million USD | -22.48% |
| 2017 Q1 | 1.7 Million USD | -17.02% |
| 2017 Q3 | 1.8 Million USD | 36.19% |
| 2017 FY | 979 Thousand USD | -52.41% |
| 2017 Q4 | 979 Thousand USD | -45.68% |
| 2016 Q1 | 1.03 Million USD | 45.34% |
| 2016 FY | 2.05 Million USD | 188.85% |
| 2016 Q2 | 403.94 Thousand USD | -60.98% |
| 2016 Q3 | 1.64 Million USD | 306.77% |
| 2016 Q4 | 2.05 Million USD | 25.2% |
| 2015 Q1 | 836.1 Thousand USD | -41.23% |
| 2015 Q3 | 669.37 Thousand USD | -47.98% |
| 2015 Q4 | 712.23 Thousand USD | 6.4% |
| 2015 FY | 712.23 Thousand USD | -49.93% |
| 2015 Q2 | 1.28 Million USD | 53.9% |
| 2014 Q4 | 1.42 Million USD | 49.4% |
| 2014 Q2 | 788.18 Thousand USD | -10.33% |
| 2014 Q1 | 878.95 Thousand USD | -9.05% |
| 2014 Q3 | 952.15 Thousand USD | 20.8% |
| 2014 FY | 1.42 Million USD | 47.2% |
| 2013 Q4 | 966.38 Thousand USD | -8.08% |
| 2013 Q2 | 1.36 Million USD | -40.35% |
| 2013 Q1 | 2.28 Million USD | 30.03% |
| 2013 FY | 966.38 Thousand USD | -44.91% |
| 2013 Q3 | 1.05 Million USD | -22.74% |
| 2012 FY | 1.75 Million USD | -72.48% |
| 2012 Q1 | 3.71 Million USD | -41.7% |
| 2012 Q4 | 1.75 Million USD | -17.92% |
| 2012 Q3 | 2.13 Million USD | -21.46% |
| 2012 Q2 | 2.72 Million USD | -26.79% |
| 2011 Q4 | 6.37 Million USD | -2.22% |
| 2011 Q2 | 7.57 Million USD | -24.45% |
| 2011 FY | 6.37 Million USD | -52.78% |
| 2011 Q1 | 10.02 Million USD | -25.78% |
| 2011 Q3 | 6.52 Million USD | -13.88% |
| 2010 Q1 | 1.12 Million USD | 3.16% |
| 2010 Q4 | 13.5 Million USD | 1464.78% |
| 2010 FY | 13.5 Million USD | 1138.25% |
| 2010 Q3 | 862.88 Thousand USD | 4.79% |
| 2010 Q2 | 823.46 Thousand USD | -26.8% |
| 2009 FY | 1.09 Million USD | -73.19% |
| 2009 Q2 | 1.09 Million USD | 28.69% |
| 2009 Q1 | 848.64 Thousand USD | -79.14% |
| 2009 Q3 | 1.46 Million USD | 34.22% |
| 2009 Q4 | 1.09 Million USD | -25.61% |
| 2008 Q3 | 4.22 Million USD | -0.04% |
| 2008 Q2 | 4.22 Million USD | -7.38% |
| 2008 FY | 4.06 Million USD | -4.52% |
| 2008 Q1 | 4.56 Million USD | 7.04% |
| 2008 Q4 | 4.06 Million USD | -3.66% |
| 2007 FY | 4.26 Million USD | 7.29% |
| 2007 Q4 | 4.26 Million USD | -0.83% |
| 2007 Q3 | 4.29 Million USD | -12.77% |
| 2007 Q2 | 4.92 Million USD | 13.58% |
| 2007 Q1 | 4.33 Million USD | 9.2% |
| 2006 Q2 | 3.69 Million USD | -19.51% |
| 2006 Q3 | 3.73 Million USD | 1.09% |
| 2006 Q4 | 3.97 Million USD | 6.32% |
| 2006 FY | 3.97 Million USD | 6.77% |
| 2006 Q1 | 4.58 Million USD | 23.42% |
| 2005 FY | 3.71 Million USD | -8.53% |
| 2005 Q1 | 3.67 Million USD | -9.63% |
| 2005 Q3 | 3.75 Million USD | 1.63% |
| 2005 Q2 | 3.69 Million USD | 0.42% |
| 2005 Q4 | 3.71 Million USD | -0.83% |
| 2004 FY | 4.06 Million USD | -1.37% |
| 2004 Q4 | 4.06 Million USD | 1.68% |
| 2004 Q3 | 3.99 Million USD | 0.1% |
| 2004 Q2 | 3.99 Million USD | 3.04% |
| 2004 Q1 | 3.87 Million USD | -5.96% |
| 2003 FY | 4.12 Million USD | -5.42% |
| 2003 Q3 | 4.28 Million USD | 14.32% |
| 2003 Q4 | 4.12 Million USD | -3.9% |
| 2003 Q1 | 4.31 Million USD | -1.02% |
| 2003 Q2 | 3.75 Million USD | -13.03% |
| 2002 Q3 | 4.01 Million USD | -4.73% |
| 2002 Q1 | 4.74 Million USD | 13.14% |
| 2002 FY | 4.35 Million USD | 3.97% |
| 2002 Q4 | 4.35 Million USD | 8.52% |
| 2002 Q2 | 4.21 Million USD | -11.12% |
| 2001 Q3 | 4.62 Million USD | 5.45% |
| 2001 Q4 | 4.19 Million USD | -9.29% |
| 2001 Q2 | 4.38 Million USD | -2.07% |
| 2001 Q1 | 4.47 Million USD | -0.96% |
| 2001 FY | 4.19 Million USD | -7.22% |
| 2000 Q1 | 5.42 Million USD | 153.32% |
| 2000 Q2 | 4.08 Million USD | -24.73% |
| 2000 Q3 | 3.59 Million USD | -12.01% |
| 2000 FY | 4.51 Million USD | 111.1% |
| 2000 Q4 | 4.51 Million USD | 25.83% |
| 1999 Q1 | 3 Million USD | -19.38% |
| 1999 Q3 | 2.39 Million USD | -7.3% |
| 1999 Q4 | 2.14 Million USD | -10.74% |
| 1999 FY | 2.14 Million USD | -42.5% |
| 1999 Q2 | 2.58 Million USD | -13.8% |
| 1998 Q4 | 3.72 Million USD | -2.28% |
| 1998 Q3 | 3.8 Million USD | -28.17% |
| 1998 Q1 | 3.89 Million USD | 44.48% |
| 1998 FY | 3.72 Million USD | 38.0% |
| 1998 Q2 | 5.3 Million USD | 36.08% |
| 1997 Q4 | 2.69 Million USD | -15.69% |
| 1997 FY | 2.69 Million USD | 0.0% |
| 1997 Q2 | 4.39 Million USD | 0.0% |
| 1997 Q3 | 3.19 Million USD | -27.27% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AbCellera Biologics Inc. | 1.48 Billion USD | 99.891% |
| Alkermes plc | 2.13 Billion USD | 99.924% |
| Agenus Inc. | 313.91 Million USD | 99.482% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 99.958% |
| Aptorum Group Limited | 20.64 Million USD | 92.127% |
| Ardelyx, Inc. | 297.57 Million USD | 99.454% |
| Arrowhead Pharmaceuticals, Inc. | 765.55 Million USD | 99.788% |
| Bicycle Therapeutics plc | 595.34 Million USD | 99.727% |
| BioXcel Therapeutics, Inc. | 73.7 Million USD | 97.795% |
| ChromaDex Corporation | 54.96 Million USD | 97.044% |
| Chimerix, Inc. | 212.77 Million USD | 99.236% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | 94.252% |
| Caribou Biosciences, Inc. | 440.96 Million USD | 99.631% |
| CRISPR Therapeutics AG | 2.22 Billion USD | 99.927% |
| Precision BioSciences, Inc. | 159.78 Million USD | 98.983% |
| Dyadic International, Inc. | 8.21 Million USD | 80.229% |
| Eton Pharmaceuticals, Inc. | 31.74 Million USD | 94.88% |
| Fortress Biotech, Inc. | 167.52 Million USD | 99.03% |
| Lantern Pharma Inc. | 43.64 Million USD | 96.277% |
| HOOKIPA Pharma Inc. | 161.33 Million USD | 98.993% |
| Inhibikase Therapeutics, Inc. | 14.5 Million USD | 88.798% |
| Incyte Corporation | 6.78 Billion USD | 99.976% |
| IO Biotech, Inc. | 150.71 Million USD | 98.922% |
| Jaguar Health, Inc. | 50.76 Million USD | 96.799% |
| Novavax, Inc. | 1.85 Billion USD | 99.912% |
| Janux Therapeutics, Inc. | 380.4 Million USD | 99.573% |
| Opthea Limited | 188.79 Million USD | 99.139% |
| Ligand Pharmaceuticals Incorporated | 833.06 Million USD | 99.805% |
| ContextLogic Inc. | 423 Million USD | 99.616% |
| MiMedx Group, Inc. | 239.04 Million USD | 99.32% |
| Pyxis Oncology, Inc. | 173.72 Million USD | 99.065% |
| TransCode Therapeutics, Inc. | 5.16 Million USD | 68.567% |
| NextCure, Inc. | 129.41 Million USD | 98.744% |
| Ocuphire Pharma, Inc. | 53.94 Million USD | 96.988% |
| Oncternal Therapeutics, Inc. | 36.72 Million USD | 95.576% |
| Outlook Therapeutics, Inc. | 32.3 Million USD | 94.969% |
| Vaxcyte, Inc. | 1.4 Billion USD | 99.885% |
| PDS Biotechnology Corporation | 59.39 Million USD | 97.264% |
| Madrigal Pharmaceuticals, Inc. | 640.54 Million USD | 99.746% |
| Pharming Group N.V. | 462.85 Million USD | 99.649% |
| Pieris Pharmaceuticals, Inc. | 38.68 Million USD | 95.799% |
| Avidity Biosciences, Inc. | 628.55 Million USD | 99.741% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | 91.413% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | 91.413% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | 99.017% |
| Sol-Gel Technologies Ltd. | 45.28 Million USD | 96.412% |
| Acelyrin, Inc. | 742.69 Million USD | 99.781% |
| Salarius Pharmaceuticals, Inc. | 6.58 Million USD | 75.328% |
| SELLAS Life Sciences Group, Inc. | 6.4 Million USD | 74.621% |
| Summit Therapeutics Inc. | 202.94 Million USD | 99.199% |
| Sensei Biotherapeutics, Inc. | 74.37 Million USD | 97.815% |
| Senti Biosciences, Inc. | 119.48 Million USD | 98.64% |
| Stoke Therapeutics, Inc. | 228.34 Million USD | 99.288% |
| Syros Pharmaceuticals, Inc. | 168.17 Million USD | 99.034% |
| Alaunos Therapeutics, Inc. | 8.26 Million USD | 80.334% |
| Telomir Pharmaceuticals, Inc. Common Stock | 4.77 Million USD | 65.96% |
| Entrada Therapeutics, Inc. | 469.19 Million USD | 99.654% |
| VistaGen Therapeutics, Inc. | 123.65 Million USD | 98.686% |
| Wave Life Sciences Ltd. | 274.94 Million USD | 99.409% |
| Sorrento Therapeutics, Inc. | 472.84 Million USD | 99.656% |
| TRACON Pharmaceuticals, Inc. | 10.1 Million USD | 83.919% |
| Barinthus Biotherapeutics plc | 214.5 Million USD | 99.242% |
| Psyence Biomedical Ltd. | 1.13 Million USD | -43.531% |
| Phathom Pharmaceuticals, Inc. | 413.84 Million USD | 99.607% |
| Immix Biopharma, Inc. | 19.92 Million USD | 91.844% |
| Keros Therapeutics, Inc. | 370.02 Million USD | 99.561% |
| MEI Pharma, Inc. | 41.37 Million USD | 96.073% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 94.985% |
| Xeris Biopharma Holdings, Inc. | 340.79 Million USD | 99.523% |
| Rigel Pharmaceuticals, Inc. | 117.22 Million USD | 98.614% |
| Fortress Biotech, Inc. | 167.52 Million USD | 99.03% |
| Precigen, Inc. | 151.04 Million USD | 98.924% |
| Clearside Biomedical, Inc. | 34.01 Million USD | 95.223% |
| AlloVir, Inc. | 190.79 Million USD | 99.148% |
| C4 Therapeutics, Inc. | 376.45 Million USD | 99.568% |
| Fate Therapeutics, Inc. | 506.21 Million USD | 99.679% |
| ImmuCell Corporation | 43.8 Million USD | 96.291% |
| IDEAYA Biosciences, Inc. | 649.31 Million USD | 99.75% |
| Onconetix, Inc. | 88.82 Million USD | 98.17% |
| PureTech Health plc | 693.97 Million USD | 99.766% |
| VYNE Therapeutics Inc. | 97.68 Million USD | 98.336% |
| Elevation Oncology, Inc. | 89.09 Million USD | 98.176% |
| Kintara Therapeutics, Inc. | 6.2 Million USD | 73.799% |
| Seer, Inc. | 436.26 Million USD | 99.628% |
| Verrica Pharmaceuticals Inc. | 81.59 Million USD | 98.009% |
| Innoviva, Inc. | 1.24 Billion USD | 99.869% |
| Aadi Bioscience, Inc. | 132.42 Million USD | 98.773% |
| ESSA Pharma Inc. | 149.12 Million USD | 98.91% |
| GlycoMimetics, Inc. | 45.31 Million USD | 96.414% |
| GT Biopharma, Inc. | 14.1 Million USD | 88.483% |
| Inhibrx Biosciences, Inc. | 307.89 Million USD | 99.472% |
| Akebia Therapeutics, Inc. | 241.7 Million USD | 99.328% |
| Catalyst Pharmaceuticals, Inc. | 471.9 Million USD | 99.656% |
| Longboard Pharmaceuticals, Inc. | 50.69 Million USD | 96.795% |
| Orchestra BioMed Holdings, Inc. | 95.21 Million USD | 98.293% |
| Alzamend Neuro, Inc. | 631.58 Thousand USD | -157.288% |
| Rocket Pharmaceuticals, Inc. | 566.34 Million USD | 99.713% |
| Aptose Biosciences Inc. | 12.92 Million USD | 87.425% |
| ZyVersa Therapeutics, Inc. | 22.11 Million USD | 92.652% |
| Soligenix, Inc. | 9.79 Million USD | 83.414% |
| Century Therapeutics, Inc. | 360.69 Million USD | 99.549% |
| Kura Oncology, Inc. | 448.93 Million USD | 99.638% |
| TScan Therapeutics, Inc. | 272.14 Million USD | 99.403% |
| Intensity Therapeutics, Inc. | 17.29 Million USD | 90.604% |
| Ocean Biomedical, Inc. | 110.91 Million USD | 98.535% |
| CytomX Therapeutics, Inc. | 205.15 Million USD | 99.208% |
| Autolus Therapeutics plc | 375.38 Million USD | 99.567% |
| Mineralys Therapeutics, Inc. | 251.63 Million USD | 99.354% |
| EyePoint Pharmaceuticals, Inc. | 355.18 Million USD | 99.542% |
| Eterna Therapeutics Inc. | 49.13 Million USD | 96.693% |
| Adaptive Biotechnologies Corporation | 661.13 Million USD | 99.754% |
| GRI Bio, Inc. | 2.95 Million USD | 45.027% |
| Xenetic Biosciences, Inc. | 10.6 Million USD | 84.677% |
| Tenaya Therapeutics, Inc. | 170.51 Million USD | 99.047% |
| IGM Biosciences, Inc. | 423.41 Million USD | 99.616% |
| INmune Bio, Inc. | 57 Million USD | 97.149% |
| Heron Therapeutics, Inc. | 222.5 Million USD | 99.27% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | 98.064% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | 93.778% |
| Entero Therapeutics, Inc. | 6.88 Million USD | 76.392% |
| Milestone Pharmaceuticals Inc. | 75.22 Million USD | 97.84% |
| X4 Pharmaceuticals, Inc. | 147.25 Million USD | 98.896% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | 99.018% |
| Coherus BioSciences, Inc. | 629.6 Million USD | 99.742% |
| Verastem, Inc. | 149.71 Million USD | 98.915% |
| Abeona Therapeutics Inc. | 64 Million USD | 97.461% |
| Pliant Therapeutics, Inc. | 512.15 Million USD | 99.683% |
| Tonix Pharmaceuticals Holding Corp. | 154.45 Million USD | 98.948% |
| Histogen Inc. | 19.07 Million USD | 91.48% |
| Aprea Therapeutics, Inc. | 22.65 Million USD | 92.826% |
| Surrozen, Inc. | 46.08 Million USD | 96.474% |
| Organovo Holdings, Inc. | 6.34 Million USD | 74.405% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | 62.285% |
| Ovid Therapeutics Inc. | 144.02 Million USD | 98.872% |
| Panbela Therapeutics, Inc. | 11.8 Million USD | 86.231% |
| CASI Pharmaceuticals, Inc. | 75.26 Million USD | 97.841% |
| Cadrenal Therapeutics, Inc. Common Stock | 8.51 Million USD | 80.926% |
| Centessa Pharmaceuticals plc | 362.96 Million USD | 99.552% |
| Hepion Pharmaceuticals, Inc. | 18.09 Million USD | 91.019% |
| Arcturus Therapeutics Holdings Inc. | 429.4 Million USD | 99.622% |
| BioRestorative Therapies, Inc. | 12.61 Million USD | 87.115% |
| Apollomics, Inc. | 55.38 Million USD | 97.066% |
| Amarin Corporation plc | 831.68 Million USD | 99.805% |
| Mesoblast Limited | 669.15 Million USD | 99.757% |
| Turnstone Biologics Corp. | 112.81 Million USD | 98.56% |
| Kymera Therapeutics, Inc. | 575.75 Million USD | 99.718% |
| Synaptogenix, Inc. | 31.11 Million USD | 94.777% |
| Tiziana Life Sciences Ltd | 12.18 Million USD | 86.663% |
| Aurinia Pharmaceuticals Inc. | 548.06 Million USD | 99.704% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | 72.328% |
| Monopar Therapeutics Inc. | 7.34 Million USD | 77.877% |
| Exelixis, Inc. | 2.94 Billion USD | 99.945% |
| Better Therapeutics, Inc. | 22.94 Million USD | 92.917% |
| Nurix Therapeutics, Inc. | 364.53 Million USD | 99.554% |
| Apellis Pharmaceuticals, Inc. | 788.73 Million USD | 99.794% |
| NLS Pharmaceutics AG | 1.84 Million USD | 12.002% |
| Dermata Therapeutics, Inc. | 7.97 Million USD | 79.633% |
| Aridis Pharmaceuticals, Inc. | 14.69 Million USD | 88.942% |
| Gritstone bio, Inc. | 177.76 Million USD | 99.086% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | 98.296% |
| TNF Pharmaceuticals, Inc. | 17.86 Million USD | 90.903% |
| Avid Bioservices, Inc. | 336.55 Million USD | 99.517% |
| Insmed Incorporated | 1.32 Billion USD | 99.878% |
| Virpax Pharmaceuticals, Inc. | 9.62 Million USD | 83.123% |
| MediWound Ltd. | 66.45 Million USD | 97.555% |
| OmniAb, Inc. | 401.98 Million USD | 99.596% |
| Alector, Inc. | 621.82 Million USD | 99.739% |
| Seres Therapeutics, Inc. | 358.6 Million USD | 99.547% |
| Checkpoint Therapeutics, Inc. | 5.37 Million USD | 69.784% |
| Viracta Therapeutics, Inc. | 56.69 Million USD | 97.134% |
| Zai Lab Limited | 1.03 Billion USD | 99.843% |
| Revance Therapeutics, Inc. | 478.45 Million USD | 99.66% |
| Aura Biosciences, Inc. | 255.07 Million USD | 99.363% |
| Lyell Immunopharma, Inc. | 750.02 Million USD | 99.783% |
| Immunic, Inc. | 54.29 Million USD | 97.007% |
| Tarsus Pharmaceuticals, Inc. | 266.22 Million USD | 99.39% |
| Veracyte, Inc. | 1.13 Billion USD | 99.857% |
| InMed Pharmaceuticals Inc. | 11.82 Million USD | 86.255% |
| FibroGen, Inc. | 423.52 Million USD | 99.616% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | 53.743% |
| Adial Pharmaceuticals, Inc. | 4.73 Million USD | 65.693% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.42 Million USD | 70.071% |
| Jazz Pharmaceuticals plc | 11.39 Billion USD | 99.986% |
| Cyclacel Pharmaceuticals, Inc. | 8.8 Million USD | 81.545% |
| Amylyx Pharmaceuticals, Inc. | 517.45 Million USD | 99.686% |
| TG Therapeutics, Inc. | 329.58 Million USD | 99.507% |
| Galecto, Inc. | 38.22 Million USD | 95.749% |
| Calithera Biosciences, Inc. | 28.67 Million USD | 94.333% |
| Fortrea Holdings Inc. | 4.35 Billion USD | 99.963% |
| KalVista Pharmaceuticals, Inc. | 235.4 Million USD | 99.31% |
| Aptevo Therapeutics Inc. | 24.84 Million USD | 93.459% |
| XBiotech Inc. | 227.24 Million USD | 99.285% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | 98.296% |
| Lyra Therapeutics, Inc. | 142.6 Million USD | 98.86% |
| Foghorn Therapeutics Inc. | 285.91 Million USD | 99.432% |
| Y-mAbs Therapeutics, Inc. | 127.86 Million USD | 98.729% |
| Theravance Biopharma, Inc. | 381.99 Million USD | 99.575% |
| Ultragenyx Pharmaceutical Inc. | 1.49 Billion USD | 99.891% |
| Metagenomi, Inc. Common Stock | 364.84 Million USD | 99.555% |
| Vaxxinity, Inc. | 44.35 Million USD | 96.336% |
| BioCryst Pharmaceuticals, Inc. | 516.96 Million USD | 99.686% |
| Gain Therapeutics, Inc. | 18.6 Million USD | 91.268% |
| Cartesian Therapeutics, Inc. | 305.05 Million USD | 99.467% |
| NexImmune, Inc. | 8.59 Million USD | 81.091% |
| Creative Medical Technology Holdings, Inc. | 10.71 Million USD | 84.835% |
| Marker Therapeutics, Inc. | 17.12 Million USD | 90.512% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 99.995% |
| Chemomab Therapeutics Ltd. | 22.15 Million USD | 92.664% |
| Scopus BioPharma Inc. | 392.26 Thousand USD | -314.261% |
| RAPT Therapeutics, Inc. | 173.32 Million USD | 99.062% |
| Ainos, Inc. | 31.84 Million USD | 94.897% |
| Pluri Inc. | 39.52 Million USD | 95.889% |
| Prothena Corporation plc | 696.38 Million USD | 99.767% |
| Adaptimmune Therapeutics plc | 282.61 Million USD | 99.425% |
| Celularity Inc. | 143.88 Million USD | 98.871% |
| Rallybio Corporation | 115.62 Million USD | 98.595% |
| Cue Biopharma, Inc. | 61.53 Million USD | 97.359% |
| MeiraGTx Holdings plc | 458.16 Million USD | 99.645% |
| Omeros Corporation | 378.26 Million USD | 99.57% |
| Humacyte, Inc. | 128.22 Million USD | 98.733% |
| Immunocore Holdings plc | 597 Million USD | 99.728% |
| Cocrystal Pharma, Inc. | 31.25 Million USD | 94.801% |
| Cidara Therapeutics, Inc. | 68.53 Million USD | 97.629% |
| Blueprint Medicines Corporation | 1.04 Billion USD | 99.845% |
| CalciMedica, Inc. | 12.18 Million USD | 86.664% |
| Cabaletta Bio, Inc. | 253.65 Million USD | 99.359% |
| Marinus Pharmaceuticals, Inc. | 170.9 Million USD | 99.049% |
| Scholar Rock Holding Corporation | 311.03 Million USD | 99.478% |
| Sana Biotechnology, Inc. | 565.29 Million USD | 99.713% |
| Pulmatrix, Inc. | 33.95 Million USD | 95.215% |
| Elicio Therapeutics, Inc. | 27.14 Million USD | 94.014% |
| Vigil Neuroscience, Inc. | 140.85 Million USD | 98.846% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | 99.875% |
| Adlai Nortye Ltd. American Depositary Shares | 130.18 Million USD | 98.752% |
| Cytokinetics, Incorporated | 824.31 Million USD | 99.803% |
| Eloxx Pharmaceuticals, Inc. | 21.12 Million USD | 92.307% |
| Nutriband Inc. | 7.51 Million USD | 78.383% |
| Protara Therapeutics, Inc. | 78.95 Million USD | 97.942% |
| Vor Biopharma Inc. | 209.82 Million USD | 99.226% |
| Roivant Sciences Ltd. | 7.22 Billion USD | 99.978% |
| Evogene Ltd. | 51.1 Million USD | 96.82% |
| ProKidney Corp. | 420.55 Million USD | 99.614% |
| Applied Therapeutics, Inc. | 54.83 Million USD | 97.036% |
| Hoth Therapeutics, Inc. | 9.52 Million USD | 82.931% |
| BridgeBio Pharma, Inc. | 546.38 Million USD | 99.703% |
| CorMedix Inc. | 82.05 Million USD | 98.02% |
| BioLineRx Ltd. | 63.92 Million USD | 97.458% |
| Tango Therapeutics, Inc. | 402.56 Million USD | 99.596% |
| Galectin Therapeutics Inc. | 28.2 Million USD | 94.238% |
| Atai Life Sciences N.V. | 293.47 Million USD | 99.446% |
| Renovaro Biosciences Inc. | 163.12 Million USD | 99.004% |
| Aerovate Therapeutics, Inc. | 127.41 Million USD | 98.725% |
| Zentalis Pharmaceuticals, Inc. | 562.02 Million USD | 99.711% |
| Sagimet Biosciences Inc. | 96.71 Million USD | 98.32% |
| MediciNova, Inc. | 66.26 Million USD | 97.548% |
| Praxis Precision Medicines, Inc. | 87.94 Million USD | 98.152% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | 63.584% |
| GeoVax Labs, Inc. | 9.28 Million USD | 82.495% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | 99.724% |
| Biomea Fusion, Inc. | 199.92 Million USD | 99.187% |
| PTC Therapeutics, Inc. | 1.9 Billion USD | 99.915% |
| Mereo BioPharma Group plc | 66.49 Million USD | 97.556% |
| Cullinan Oncology, Inc. | 485.09 Million USD | 99.665% |
| Syndax Pharmaceuticals, Inc. | 612.88 Million USD | 99.735% |
| Absci Corporation | 234.48 Million USD | 99.307% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | 77.785% |
| 4D Molecular Therapeutics, Inc. | 339.89 Million USD | 99.522% |
| Dyne Therapeutics, Inc. | 165.08 Million USD | 99.016% |
| Kiniksa Pharmaceuticals, Ltd. | 526.32 Million USD | 99.691% |
| Ventyx Biosciences, Inc. | 277.69 Million USD | 99.415% |
| Allakos Inc. | 243.61 Million USD | 99.333% |
| Imunon, Inc. | 21.91 Million USD | 92.586% |
| Fulcrum Therapeutics, Inc. | 257.69 Million USD | 99.369% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | 99.739% |
| BioAtla, Inc. | 119.65 Million USD | 98.642% |
| NLS Pharmaceutics AG | 1.84 Million USD | 12.002% |
| Bio-Path Holdings, Inc. | 3.22 Million USD | 49.534% |
| Allogene Therapeutics, Inc. | 642.83 Million USD | 99.747% |
| Larimar Therapeutics, Inc. | 95.93 Million USD | 98.306% |
| XOMA Corporation | 234.3 Million USD | 99.306% |
| Kezar Life Sciences, Inc. | 221.23 Million USD | 99.265% |
| Cara Therapeutics, Inc. | 125.84 Million USD | 98.709% |
| aTyr Pharma, Inc. | 122.06 Million USD | 98.669% |
| Aligos Therapeutics, Inc. | 153.9 Million USD | 98.944% |
| Akero Therapeutics, Inc. | 580.27 Million USD | 99.72% |
| Viridian Therapeutics, Inc. | 490.42 Million USD | 99.669% |
| Eliem Therapeutics, Inc. | 110.46 Million USD | 98.529% |
| EyeGate Pharmaceuticals, Inc. | 15.15 Million USD | 89.279% |
| Akari Therapeutics, Plc | 4.35 Million USD | 62.687% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | 90.462% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 99.906% |
| Lexaria Bioscience Corp. | 3.08 Million USD | 47.308% |
| UroGen Pharma Ltd. | 178.31 Million USD | 99.089% |
| Sutro Biopharma, Inc. | 470.73 Million USD | 99.655% |
| ZIVO Bioscience, Inc. | 555.71 Thousand USD | -192.416% |
| Orgenesis Inc. | 14.55 Million USD | 88.833% |
| Entera Bio Ltd. | 11.76 Million USD | 86.188% |
| GH Research PLC | 226.3 Million USD | 99.282% |
| Lisata Therapeutics, Inc. | 54.69 Million USD | 97.029% |
| Reneo Pharmaceuticals, Inc. | 107.43 Million USD | 98.487% |
| Xencor, Inc. | 952.69 Million USD | 99.829% |
| 60 Degrees Pharmaceuticals, Inc. | 7.78 Million USD | 79.123% |
| Replimune Group, Inc. | 487.72 Million USD | 99.667% |
| Coeptis Therapeutics Holdings, Inc. | 8.07 Million USD | 79.866% |
| Vanda Pharmaceuticals Inc. | 648.44 Million USD | 99.749% |
| Lexaria Bioscience Corp. | 3.08 Million USD | 47.308% |
| Portage Biotech Inc. | 7.77 Million USD | 79.11% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | 63.584% |
| Olema Pharmaceuticals, Inc. | 276.94 Million USD | 99.413% |
| OncoCyte Corporation | 74.89 Million USD | 97.83% |
| Qualigen Therapeutics, Inc. | 2.03 Million USD | 20.079% |
| Processa Pharmaceuticals, Inc. | 5.78 Million USD | 71.918% |
| Purple Biotech Ltd. | 44.3 Million USD | 96.332% |
| CollPlant Biotechnologies Ltd. | 34.12 Million USD | 95.238% |
| scPharmaceuticals Inc. | 94.47 Million USD | 98.28% |
| ProMIS Neurosciences, Inc. | 18.04 Million USD | 90.995% |
| HilleVax, Inc. | 344.43 Million USD | 99.528% |
| NeuroSense Therapeutics Ltd. | 3.17 Million USD | 48.835% |
| Tharimmune, Inc. | 10.94 Million USD | 85.155% |
| Genprex, Inc. | 10.67 Million USD | 84.771% |
| Neumora Therapeutics, Inc. Common Stock | 496.19 Million USD | 99.673% |
| Atossa Therapeutics, Inc. | 96.25 Million USD | 98.312% |
| XTL Biopharmaceuticals Ltd. | 2.42 Million USD | 33.017% |
| Virios Therapeutics, Inc. | 4.16 Million USD | 60.989% |
| OKYO Pharma Limited | 1.54 Million USD | -5.433% |
| Savara Inc. | 177.56 Million USD | 99.085% |
| Curis, Inc. | 77.28 Million USD | 97.897% |
| Daré Bioscience, Inc. | 21.28 Million USD | 92.365% |
| Carmell Therapeutics Corporation | 63.94 Million USD | 97.459% |
| Titan Pharmaceuticals, Inc. | 8.08 Million USD | 79.904% |
| Achieve Life Sciences, Inc. | 19.37 Million USD | 91.611% |
| BeiGene, Ltd. | 5.8 Billion USD | 99.972% |
| Kiromic BioPharma, Inc. | 12.16 Million USD | 86.646% |
| Revolution Medicines, Inc. Warrant | 2.08 Billion USD | 99.922% |
| Protagonist Therapeutics, Inc. | 357.95 Million USD | 99.546% |
| Erasca, Inc. | 395.29 Million USD | 99.589% |
| bluebird bio, Inc. | 619.16 Million USD | 99.738% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | 62.414% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 99.976% |
| DBV Technologies S.A. | 182.98 Million USD | 99.112% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | 62.414% |
| Moderna, Inc. | 18.42 Billion USD | 99.991% |
| Vincerx Pharma, Inc. | 18.21 Million USD | 91.08% |
| Fresh Tracks Therapeutics, Inc. | 11.58 Million USD | 85.974% |
| Molecular Templates, Inc. | 35.38 Million USD | 95.407% |
| Acrivon Therapeutics, Inc. Common Stock | 138.26 Million USD | 98.825% |
| Travere Therapeutics, Inc. | 788.91 Million USD | 99.794% |
| Monte Rosa Therapeutics, Inc. | 303.75 Million USD | 99.465% |
| Spruce Biosciences, Inc. | 103.94 Million USD | 98.437% |
| Celldex Therapeutics, Inc. | 465.62 Million USD | 99.651% |
| Cogent Biosciences, Inc. | 313.43 Million USD | 99.482% |
| MacroGenics, Inc. | 306.82 Million USD | 99.47% |
| RenovoRx, Inc. | 1.46 Million USD | -10.846% |
| Adicet Bio, Inc. | 207.29 Million USD | 99.216% |
| Prime Medicine, Inc. | 193.85 Million USD | 99.162% |
| Aditxt, Inc. | 44.57 Million USD | 96.355% |
| Adagene Inc. | 115.72 Million USD | 98.596% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | 63.517% |
| Quantum-Si incorporated | 298.25 Million USD | 99.455% |
| Maravai LifeSciences Holdings, Inc. | 1.48 Billion USD | 99.891% |
| Acurx Pharmaceuticals, Inc. | 7.7 Million USD | 78.921% |
| Voyager Therapeutics, Inc. | 351.28 Million USD | 99.537% |
| SciSparc Ltd. | 11.18 Million USD | 85.468% |
| Vericel Corporation | 353.65 Million USD | 99.541% |
| Revelation Biosciences, Inc. | 12.21 Million USD | 86.694% |
| Minerva Neurosciences, Inc. | 56.9 Million USD | 97.144% |
| Generation Bio Co. | 374.75 Million USD | 99.566% |
| Astria Therapeutics, Inc. | 254.66 Million USD | 99.362% |
| Black Diamond Therapeutics, Inc. | 158.56 Million USD | 98.975% |
| Arcutis Biotherapeutics, Inc. | 341.36 Million USD | 99.524% |
| Invivyd, Inc. | 229.18 Million USD | 99.291% |
| Relay Therapeutics, Inc. | 843.98 Million USD | 99.807% |
| Quoin Pharmaceuticals, Ltd. | 12.16 Million USD | 86.647% |
| Spero Therapeutics, Inc. | 182.39 Million USD | 99.109% |
| Artelo Biosciences, Inc. | 20.42 Million USD | 92.044% |
| 2seventy bio, Inc. | 565.42 Million USD | 99.713% |
| ADMA Biologics, Inc. | 329.18 Million USD | 99.506% |
| Clene Inc. | 52.34 Million USD | 96.895% |
| Capricor Therapeutics, Inc. | 58.73 Million USD | 97.233% |
| Boundless Bio, Inc. Common Stock | 129.89 Million USD | 98.749% |
| GeoVax Labs, Inc. | 9.28 Million USD | 82.495% |
| Recursion Pharmaceuticals, Inc. | 653.69 Million USD | 99.751% |
| Citius Pharmaceuticals, Inc. | 103.61 Million USD | 98.432% |
| Contineum Therapeutics, Inc. Class A Common Stock | 130.38 Million USD | 98.754% |
| Relmada Therapeutics, Inc. | 97.55 Million USD | 98.334% |
| Finch Therapeutics Group, Inc. | 70.99 Million USD | 97.711% |
| ALX Oncology Holdings Inc. | 242.55 Million USD | 99.33% |
| Vir Biotechnology, Inc. | 1.96 Billion USD | 99.917% |
| Evaxion Biotech A/S | 12.88 Million USD | 87.392% |
| Ocular Therapeutix, Inc. | 252.06 Million USD | 99.355% |
| Verve Therapeutics, Inc. | 752.68 Million USD | 99.784% |
| Trevena, Inc. | 40.6 Million USD | 95.998% |
| Surrozen, Inc. | 46.08 Million USD | 96.474% |
| Tyra Biosciences, Inc. | 225.85 Million USD | 99.281% |
| Cingulate Inc. | 3.49 Million USD | 53.458% |
| Galmed Pharmaceuticals Ltd. | 16.62 Million USD | 90.228% |
| Unity Biotechnology, Inc. | 65.69 Million USD | 97.526% |
| Tenax Therapeutics, Inc. | 11.68 Million USD | 86.093% |
| Terns Pharmaceuticals, Inc. | 268.51 Million USD | 99.395% |
| ACADIA Pharmaceuticals Inc. | 748.95 Million USD | 99.783% |
| Connect Biopharma Holdings Limited | 125.89 Million USD | 98.709% |
| Clearmind Medicine Inc. | 4.32 Million USD | 62.422% |
| Kronos Bio, Inc. | 213.27 Million USD | 99.238% |
| Bolt Biotherapeutics, Inc. | 159.78 Million USD | 98.983% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | 81.018% |
| Viking Therapeutics, Inc. | 368.49 Million USD | 99.559% |
| Statera Biopharma, Inc. | 21.16 Million USD | 92.324% |
| ImmunityBio, Inc. | 504.45 Million USD | 99.678% |
| Korro Bio, Inc. | 221.66 Million USD | 99.267% |
| Kineta, Inc. | 10.28 Million USD | 84.194% |
| BioVie Inc. | 25.2 Million USD | 93.554% |
| Codexis, Inc. | 136.56 Million USD | 98.81% |
| Celularity Inc. | 143.88 Million USD | 98.871% |
| Crinetics Pharmaceuticals, Inc. | 635.35 Million USD | 99.744% |
| Celcuity Inc. | 191.21 Million USD | 99.15% |
| Virax Biolabs Group Limited | 5.48 Million USD | 70.368% |
| Cibus, Inc. | 544.41 Million USD | 99.702% |
| Eledon Pharmaceuticals, Inc. | 125.89 Million USD | 98.709% |
| eFFECTOR Therapeutics, Inc. | 20.54 Million USD | 92.09% |
| IN8bio, Inc. | 33.7 Million USD | 95.179% |
| Kodiak Sciences Inc. | 479.37 Million USD | 99.661% |
| Annexon, Inc. | 297.67 Million USD | 99.454% |
| Adverum Biotechnologies, Inc. | 173.01 Million USD | 99.061% |
| Assembly Biosciences, Inc. | 137.46 Million USD | 98.818% |
| Avalo Therapeutics, Inc. | 20.99 Million USD | 92.259% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 99.946% |
| Eyenovia, Inc. | 28.77 Million USD | 94.354% |
| Puma Biotechnology, Inc. | 230.52 Million USD | 99.295% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | 77.506% |
| Xilio Therapeutics, Inc. | 60.92 Million USD | 97.333% |
| Arcellx, Inc. | 825.13 Million USD | 99.803% |
| Cardiff Oncology, Inc. | 81.63 Million USD | 98.009% |
| Enanta Pharmaceuticals, Inc. | 462.27 Million USD | 99.648% |
| Regulus Therapeutics Inc. | 30.75 Million USD | 94.715% |
| Moolec Science SA | 24.05 Million USD | 93.244% |
| Acumen Pharmaceuticals, Inc. | 310.12 Million USD | 99.476% |
| Geron Corporation | 394.07 Million USD | 99.588% |
| LAVA Therapeutics N.V. | 101.71 Million USD | 98.402% |
| Royalty Pharma plc | 16.38 Billion USD | 99.99% |
| Atea Pharmaceuticals, Inc. | 594.96 Million USD | 99.727% |
| Greenwich LifeSciences, Inc. | 6.99 Million USD | 76.769% |
| TFF Pharmaceuticals, Inc. | 12.02 Million USD | 86.489% |
| Mersana Therapeutics, Inc. | 226.06 Million USD | 99.281% |
| Humacyte, Inc. | 128.22 Million USD | 98.733% |
| Structure Therapeutics Inc. | 482.01 Million USD | 99.663% |
| 89bio, Inc. | 596.26 Million USD | 99.727% |
| PMV Pharmaceuticals, Inc. | 252.15 Million USD | 99.356% |
| Avenue Therapeutics, Inc. | 1.85 Million USD | 12.162% |
| Genelux Corporation | 27.89 Million USD | 94.174% |
| Trevi Therapeutics, Inc. | 89.4 Million USD | 98.182% |
| Lexicon Pharmaceuticals, Inc. | 229.42 Million USD | 99.292% |
| Notable Labs, Ltd. | 19.54 Million USD | 91.684% |
| Liquidia Corporation | 120.43 Million USD | 98.651% |
| Mustang Bio, Inc. | 17.74 Million USD | 90.841% |
| Immunovant, Inc. | 666.71 Million USD | 99.756% |
| Quantum-Si incorporated | 298.25 Million USD | 99.455% |
| Arbutus Biopharma Corporation | 144.4 Million USD | 98.875% |
| DiaMedica Therapeutics Inc. | 54.16 Million USD | 97.0% |
| Vera Therapeutics, Inc. | 175.54 Million USD | 99.074% |
| Acasti Pharma Inc. | 73.3 Million USD | 97.783% |
| MiNK Therapeutics, Inc. | 4.55 Million USD | 64.304% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | 93.778% |
| Xenon Pharmaceuticals Inc. | 964.79 Million USD | 99.832% |
| Elevai Labs, Inc. Common Stock | 5.18 Million USD | 68.689% |
| NeuroBo Pharmaceuticals, Inc. | 22.78 Million USD | 92.867% |
| Tempest Therapeutics, Inc. | 51.6 Million USD | 96.851% |
| Soleno Therapeutics, Inc. | 180.69 Million USD | 99.101% |
| PepGen Inc. | 143.05 Million USD | 98.864% |
| Moleculin Biotech, Inc. | 38.21 Million USD | 95.748% |
| United Therapeutics Corporation | 7.16 Billion USD | 99.977% |
| Nuvectis Pharma, Inc. | 19.18 Million USD | 91.53% |
| Solid Biosciences Inc. | 164.93 Million USD | 99.015% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | 72.328% |
| Immuneering Corporation | 102.58 Million USD | 98.416% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | 62.285% |
| Silo Pharma, Inc. | 7.74 Million USD | 79.022% |
| Belite Bio, Inc | 94.64 Million USD | 98.283% |
| XOMA Corporation | 234.3 Million USD | 99.306% |
| ARS Pharmaceuticals, Inc. | 233.18 Million USD | 99.303% |
| Bionomics Limited | 27.64 Million USD | 94.123% |
| Apogee Therapeutics, Inc. | 401.4 Million USD | 99.595% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | 98.487% |
| uniQure N.V. | 831.68 Million USD | 99.805% |
| Cassava Sciences, Inc. | 151.66 Million USD | 98.929% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | 63.517% |
| Poseida Therapeutics, Inc. | 273.88 Million USD | 99.407% |
| Forte Biosciences, Inc. | 38.98 Million USD | 95.831% |
| Anebulo Pharmaceuticals, Inc. | 4.07 Million USD | 60.104% |
| Enlivex Therapeutics Ltd. | 36.83 Million USD | 95.588% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | 77.506% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | 53.743% |
| FibroBiologics, Inc. Common Stock | 11.82 Million USD | 86.253% |
| Altimmune, Inc. | 210.64 Million USD | 99.229% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | 99.791% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | 98.487% |
| Compugen Ltd. | 121.33 Million USD | 98.661% |
| Peak Bio, Inc. | 2.59 Million USD | 37.414% |
| Zevra Therapeutics, Inc. | 172.32 Million USD | 99.057% |
| Benitec Biopharma Inc. | 52.21 Million USD | 96.888% |
| Spyre Therapeutics, Inc. | 341.85 Million USD | 99.525% |
| NKGen Biotech, Inc. Common Stock | 34.77 Million USD | 95.327% |
| Zura Bio Limited | 100.84 Million USD | 98.389% |
| PolyPid Ltd. | 15.37 Million USD | 89.429% |
| Aileron Therapeutics, Inc. | 119.28 Million USD | 98.638% |
| NKGen Biotech, Inc. Warrants | 34.77 Million USD | 95.327% |
| Instil Bio, Inc. | 325.63 Million USD | 99.501% |
| argenx SE | 4.54 Billion USD | 99.964% |
| Immunome, Inc. | 148.54 Million USD | 98.906% |
| Compass Therapeutics, Inc. | 156.87 Million USD | 98.964% |
| Verona Pharma plc | 308.12 Million USD | 99.473% |
| enGene Holdings Inc. Warrants | 86.95 Million USD | 98.131% |
| Shattuck Labs, Inc. | 159.56 Million USD | 98.982% |
| CervoMed Inc. | 9.97 Million USD | 83.705% |
| LENZ Therapeutics, Inc. | 188.45 Million USD | 99.138% |
| Plus Therapeutics, Inc. | 11.38 Million USD | 85.731% |
| Dianthus Therapeutics, Inc. | 179.4 Million USD | 99.094% |
| Moolec Science SA | 24.05 Million USD | 93.244% |
| Enveric Biosciences, Inc. | 6.11 Million USD | 73.437% |
| Inovio Pharmaceuticals, Inc. | 172.94 Million USD | 99.06% |
| AnaptysBio, Inc. | 452.38 Million USD | 99.641% |
| Design Therapeutics, Inc. | 289.64 Million USD | 99.439% |
| Leap Therapeutics, Inc. | 72.82 Million USD | 97.769% |
| NeurAxis, Inc. | 509.49 Thousand USD | -218.941% |
| Seelos Therapeutics, Inc. | 5.41 Million USD | 70.007% |
| Lumos Pharma, Inc. | 40.63 Million USD | 96.001% |
| Achilles Therapeutics plc | 161.45 Million USD | 98.994% |
| enGene Holdings Inc. Common Stock | 86.95 Million USD | 98.131% |
| 180 Life Sciences Corp. | 5.25 Million USD | 69.103% |
| Opiant Pharmaceuticals, Inc. | 70.42 Million USD | 97.693% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | 81.018% |
| Nutriband Inc. | 7.51 Million USD | 78.383% |
| ORIC Pharmaceuticals, Inc. | 254.68 Million USD | 99.362% |
| CG Oncology, Inc. Common stock | 199.3 Million USD | 99.185% |
| Fractyl Health, Inc. Common Stock | 76.21 Million USD | 97.868% |
| Rani Therapeutics Holdings, Inc. | 57.91 Million USD | 97.194% |
| MoonLake Immunotherapeutics | 526.54 Million USD | 99.691% |
| Palisade Bio, Inc. | 14.05 Million USD | 88.436% |
| Tourmaline Bio, Inc. | 210.29 Million USD | 99.227% |
| Beam Therapeutics Inc. | 1.45 Billion USD | 99.889% |
| Neurogene Inc. | 222.57 Million USD | 99.27% |
| Mirum Pharmaceuticals, Inc. | 646.62 Million USD | 99.749% |
| AEON Biopharma, Inc. | 6.84 Million USD | 76.26% |
| CARGO Therapeutics, Inc. Common Stock | 453.03 Million USD | 99.641% |
| Sesen Bio, Inc. | 189.17 Million USD | 99.141% |
| Enliven Therapeutics, Inc. | 271.86 Million USD | 99.402% |
| Kiora Pharmaceuticals, Inc. | 13.71 Million USD | 88.149% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | 99.792% |
| Taysha Gene Therapies, Inc. | 266.99 Million USD | 99.391% |
| Athira Pharma, Inc. | 160.24 Million USD | 98.986% |
| Vaccinex, Inc. | 3.63 Million USD | 55.246% |
| HCW Biologics Inc. | 28.51 Million USD | 94.301% |
| XOMA Corporation | 234.3 Million USD | 99.306% |
| Nektar Therapeutics | 398.03 Million USD | 99.592% |
| Arvinas, Inc. | 1.3 Billion USD | 99.875% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | 90.462% |
| Merus N.V. | 458.49 Million USD | 99.646% |
| Omega Therapeutics, Inc. | 204.36 Million USD | 99.205% |
| Quince Therapeutics, Inc. | 180.2 Million USD | 99.098% |
| Rezolute, Inc. | 132.73 Million USD | 98.776% |
| Clene Inc. | 52.34 Million USD | 96.895% |
| Indaptus Therapeutics, Inc. | 14.92 Million USD | 89.111% |
| BeyondSpring Inc. | 24.8 Million USD | 93.45% |
| Synlogic, Inc. | 75.55 Million USD | 97.849% |
| Allarity Therapeutics, Inc. | 11.86 Million USD | 86.301% |
| Phio Pharmaceuticals Corp. | 9.36 Million USD | 82.646% |
| Peak Bio, Inc. | 2.59 Million USD | 37.414% |
| Werewolf Therapeutics, Inc. | 174.83 Million USD | 99.071% |
| Krystal Biotech, Inc. | 818.35 Million USD | 99.801% |
| Karyopharm Therapeutics Inc. | 240.43 Million USD | 99.324% |
| SpringWorks Therapeutics, Inc. | 725.78 Million USD | 99.776% |
| Lipella Pharmaceuticals Inc. | 3.57 Million USD | 54.573% |
| MannKind Corporation | 475.19 Million USD | 99.658% |
| Ikena Oncology, Inc. | 192.09 Million USD | 99.154% |
| Cyclerion Therapeutics, Inc. | 13.37 Million USD | 87.85% |
| Gyre Therapeutics, Inc. | 116.53 Million USD | 98.606% |
| Gossamer Bio, Inc. | 311.91 Million USD | 99.479% |
| CohBar, Inc. | 16.36 Million USD | 90.071% |
| Cognition Therapeutics, Inc. | 35.16 Million USD | 95.379% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | 77.785% |
| Legend Biotech Corporation | 1.84 Billion USD | 99.912% |
| Mural Oncology plc | 301.74 Million USD | 99.461% |
| Biora Therapeutics, Inc. | 31.21 Million USD | 94.794% |
| PaxMedica, Inc. Common Stock | 5.68 Million USD | 71.393% |
| Disc Medicine, Inc. | 367.99 Million USD | 99.558% |
| Champions Oncology, Inc. | 26.13 Million USD | 93.782% |
| REGENXBIO Inc. | 573.97 Million USD | 99.717% |
| Ensysce Biosciences, Inc. | 2.7 Million USD | 39.994% |
| Anavex Life Sciences Corp. | 154.38 Million USD | 98.947% |
| Cellectar Biosciences, Inc. | 12.07 Million USD | 86.543% |
| Edgewise Therapeutics, Inc. | 340.03 Million USD | 99.522% |
| Vaxart, Inc. | 91.83 Million USD | 98.23% |
| PharmaCyte Biotech, Inc. | 59.9 Million USD | 97.287% |
| Aldeyra Therapeutics, Inc. | 148.32 Million USD | 98.904% |
| Cellectis S.A. | 334.27 Million USD | 99.514% |
| Longeveron Inc. | 12.17 Million USD | 86.656% |
| Repare Therapeutics Inc. | 253.9 Million USD | 99.36% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 99.95% |
| Inozyme Pharma, Inc. | 200.84 Million USD | 99.191% |
| Revolution Medicines, Inc. | 2.08 Billion USD | 99.922% |
| Third Harmonic Bio, Inc. | 277.71 Million USD | 99.415% |
| ArriVent BioPharma, Inc. Common Stock | 163.09 Million USD | 99.004% |
| AN2 Therapeutics, Inc. | 138.74 Million USD | 98.829% |
| Anixa Biosciences, Inc. | 25.52 Million USD | 93.633% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 99.993% |
| Denali Therapeutics Inc. | 1.15 Billion USD | 99.859% |
| Revelation Biosciences, Inc. | 12.21 Million USD | 86.694% |
| Veru Inc. | 50.59 Million USD | 96.788% |
| Corvus Pharmaceuticals, Inc. | 45.55 Million USD | 96.433% |
| Cingulate Inc. | 3.49 Million USD | 53.458% |
| Passage Bio, Inc. | 150.54 Million USD | 98.921% |
| Context Therapeutics Inc. | 16.06 Million USD | 89.883% |
| Exicure, Inc. | 11.58 Million USD | 85.967% |
| Day One Biopharmaceuticals, Inc. | 376.04 Million USD | 99.568% |
| Oramed Pharmaceuticals Inc. | 161.64 Million USD | 98.995% |
| Scinai Immunotherapeutics Ltd. | 17.47 Million USD | 90.699% |
| Rhythm Pharmaceuticals, Inc. | 332.74 Million USD | 99.512% |
| Nuvalent, Inc. | 732.38 Million USD | 99.778% |
| ABVC BioPharma, Inc. | 14.94 Million USD | 89.126% |
| Carisma Therapeutics, Inc. | 89.55 Million USD | 98.185% |
| Unicycive Therapeutics, Inc. | 14.19 Million USD | 88.549% |
| OmniAb, Inc. | 401.98 Million USD | 99.596% |
| Anew Medical, Inc. | 19.45 Million USD | 91.648% |
| Fennec Pharmaceuticals Inc. | 26.72 Million USD | 93.92% |
| Lipocine Inc. | 23 Million USD | 92.935% |
| Lexeo Therapeutics, Inc. Common Stock | 139.8 Million USD | 98.838% |
| Nautilus Biotechnology, Inc. | 305.56 Million USD | 99.468% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | 98.064% |
| G1 Therapeutics, Inc. | 121.54 Million USD | 98.663% |
| Bellerophon Therapeutics, Inc. | 7.93 Million USD | 79.521% |
| Sage Therapeutics, Inc. | 882.27 Million USD | 99.816% |
| Ocugen, Inc. | 64.54 Million USD | 97.482% |
| Mind Medicine (MindMed) Inc. | 124.54 Million USD | 98.695% |
| Q32 Bio Inc. | 306.11 Million USD | 99.469% |
| Brainstorm Cell Therapeutics Inc. | 4.2 Million USD | 61.383% |
| Alumis Inc. Common Stock | 89.61 Million USD | 98.187% |
| Equillium, Inc. | 50.53 Million USD | 96.784% |
| Kyverna Therapeutics, Inc. | 75.19 Million USD | 97.839% |
| Coya Therapeutics, Inc. | 41.27 Million USD | 96.063% |
| CNS Pharmaceuticals, Inc. | 1.7 Million USD | 4.46% |
| Galera Therapeutics, Inc. | 26.14 Million USD | 93.784% |
| Evelo Biosciences, Inc. | 64.44 Million USD | 97.478% |
| Comera Life Sciences Holdings, Inc. | 3.72 Million USD | 56.401% |
| Dominari Holdings Inc. | 57.55 Million USD | 97.177% |
| Edesa Biotech, Inc. | 8.89 Million USD | 81.722% |
| vTv Therapeutics Inc. | 11.01 Million USD | 85.251% |
| Bio-Techne Corporation | 2.81 Billion USD | 99.942% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | 99.827% |
| Harmony Biosciences Holdings, Inc. | 811.44 Million USD | 99.8% |
| Prelude Therapeutics Incorporated | 277.66 Million USD | 99.415% |
| Candel Therapeutics, Inc. | 41.7 Million USD | 96.103% |
| iTeos Therapeutics, Inc. | 667.58 Million USD | 99.757% |
| Nkarta, Inc. | 378.88 Million USD | 99.571% |
| BioCardia, Inc. | 2.98 Million USD | 45.598% |
| Iterum Therapeutics plc | 26.25 Million USD | 93.812% |